Monotargeting anticancer agents suffer from resistance and target nonspecificity concerns,
which can be tackled with a multitargeting approach. The combined treatment with HDAC …

The emergence of resistance to PARP1 inhibitors poses a current therapeutic challenge,
necessitating the development of novel strategies to overcome this obstacle. The present …

Aberrant signaling of EGFR (ErbB) family members, in particular epidermal growth factor
receptor (EGFR) and human epidermal growth factor 2 (HER2), is associated with the …

Computer-aided drug design (CADD) has become an effective tool for the development of
therapeutics. CADD approaches parallelly assist the main drug discovery pipeline in many …

The treatment of cancer has been one of the most significant challenges for the medical
field. Further research on the signal transduction pathway of tumor cells is driving the rapid …

Three new derivatives of tetrahydrocurcumin 6, 7 and 9 have been prepared as potent
antitumor agents using copper (II)-catalyzed 'click chemistry'. Their structures were identified …

Acute leukemia is a highly heterogeneous disease; therefore, combination therapy is
commonly used for patient treatment. Drug–drug interaction is a major concern of combined …

Indoline framework is often perpended as a privileged heterocycle present in medicinally
valuable compounds of natural and synthetic origin. This review article presents the rational …

Estrogen receptor alpha (ERα), a nuclear transcription factor, is a well-validated therapeutic
target for more than 70% of all breast cancers (BCs). Antagonizing ERα either by selective …

Docking calculations can accelerate drug discovery by predicting the bound poses of
ligands for a targeted protein. However, it is not clear which docking methods work best …